Genematrix is a leading brand specializing in multiplex molecular diagnostics, offering innovative solutions for a healthier life. With a focus on developing cutting-edge technologies in the field of molecular diagnostics, Genematrix is at the forefront of the high-technology biotechnology sector. The Molecular Diagnostic market, known for its high growth rates, relies heavily on advanced countries due to the dominance of global companies in core technologies.

However, Genematrix has successfully developed its own globally competitive technologies through collaborations with domestic and international research institutes and companies. These molecular diagnostic technologies, such as C-TAG, Omniplex, EnCleap, TriO, and REMP, are utilized in the diagnosis of diseases such as hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections. Known for its advantage in multiplexing, Genematrix is a leading player in the international market, enabling the simultaneous detection of multiple genes or pathogens with a single test.

Additionally, Genematrix is dedicated to the development of vaccines for disease prevention and natural pharmaceutical materials for health improvement and treatment. With a comprehensive approach to diagnosis, prevention, and treatment, Genematrix aims to become a leading biotechnology company globally